EMA/PE/0000245628 - paediatric investigation plan

ivonescimab
PIPHuman

Icelandic is available via eTranslation, the European Commission's machine translation service.

Translate to Icelandic | Important information about machine translation

Key facts

Active substance
ivonescimab
Therapeutic area
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Decision number
EMA/PE/0000245628
PIP number
EMA/PE/0000245628
Pharmaceutical form(s)
All pharmaceutical forms
Condition(s) / indication(s)
Treatment of head and neck epithelial malignant neoplasms
Route(s) of administration
All routes of administration
Contact for public enquiries

Summit (Oxford) Limited
E-mail: medinfo@smmttx.com 
Tel.:  +1 6503820001

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date
Compliance check done
Nei

Decision

Share this page